Next Generation Material Infused with Proprietary
ProBalance Technology™ to Help Maintain Ocular Surface Homeostasis
and Help Reduce Contact Lens Dryness, Which Affects More Than Half
of Lens Wearers in the United
States
LAVAL, Quebec, Aug. 17, 2020 /CNW/ -- Bausch + Lomb, a
leading global eye health business of Bausch Health Companies
Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced the launch
of Bausch + Lomb INFUSE™ silicone hydrogel (SiHy) daily disposable
contact lens, the only SiHy daily disposable with a next generation
material infused with ProBalance Technology™ to help ocular surface
homeostasis and help reduce symptoms of contact lens dryness, which
is experienced by approximately half1 of the 45 million
lens wearers in the United
States.2,3
"Our Bausch + Lomb INFUSE SiHy daily disposable lens combines
innovative design and advanced technology to provide support for
dryness as a barrier to contact lens wear," said Joe Gordon, U.S. president, Bausch + Lomb.
"Bausch + Lomb INFUSE is designed with an advanced silicone
hydrogel daily disposable lens to help reduce symptoms of contact
lens dryness and is a testament to our ongoing commitment to apply
the latest science to meet the needs of patients and eye care
providers."
Bausch + Lomb INFUSE contact lenses feature a
next-generation SiHy daily disposable lens material (kalifilcon
A) and ProBalance Technology™ that work together to help
maintain ocular surface homeostasis to help reduce contact lens
dryness and discomfort. The ProBalance
Technology™ formula is infused into the lens
material during the manufacturing process. These proprietary
ingredients are released during lens wear. Bausch + Lomb INFUSE
combines exceptional breathability for healthy lens wear with the
highest moisture content and lowest modulus among SiHy daily
disposables*, and it maintains 96% of its moisture for a full 16
hours.
"Many of my patients believe they have to sacrifice comfort for
vision correction due to contact lens dryness. I'm excited to be
able to offer them a new lens design that goes beyond material
characteristics to look at how the lens material and solution
technology can work together," said Arthur
B. Epstein, O.D., Director of Clinical Research and the Dry
Eye and Ocular Surface Disease Center, Phoenix Eye Care. "By
understanding the ocular environment in which a contact lens
resides, Bausch + Lomb was able to address patients' needs by
seeking a different approach and design that helps maintain ocular
surface homeostasis to help reduce symptoms of contact lens
dryness."
For more information on Bausch + Lomb INFUSE contact lenses,
visit www.BauschInfuse.com and www.BauschInfuse.com/ECP.
About Bausch + Lomb
Bausch + Lomb, a leading global
eye health business of Bausch Health Companies Inc., is solely
focused on helping people see better to live better. Its core
businesses include over-the-counter products, dietary supplements,
eye care products, ophthalmic pharmaceuticals, contact lenses, lens
care products, ophthalmic surgical devices and instruments. Bausch
+ Lomb develops, manufactures and markets one of the most
comprehensive product portfolios in the industry, which is
available in more than 100 countries. For more information, visit
www.bausch.com.
About Bausch Health
Bausch Health Companies Inc.
(NYSE/TSX: BHC) is a global company whose mission is to improve
people's lives with our health care products. We develop,
manufacture and market a range of pharmaceutical, medical device
and over-the-counter products, primarily in the therapeutic areas
of eye health, gastroenterology and dermatology. We are delivering
on our commitments as we build an innovative company dedicated to
advancing global health. More information can be found at
www.bauschhealth.com.
Forward-looking Statements
This news release may contain forward-looking statements, which may
generally be identified by the use of the words
"anticipates," "expects," "intends," "plans," "should," "could," "would," "may,"
"believes," "estimates," "potential," "target," or "continue" and
variations or similar expressions. These statements are based upon
the current expectations and beliefs of management and are subject
to certain risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, the risks and uncertainties discussed in the Bausch
Health's most recent annual report on Form 10-K and detailed from
time to time in Bausch Health's other filings with the U.S.
Securities and Exchange Commission and the Canadian Securities
Administrators, which factors are incorporated herein by reference.
They also include, but are not limited to, risks and uncertainties
caused by or relating to the evolving COVID-19 pandemic, and the
fear of that pandemic and its potential effects, the severity,
duration and future impact of which are highly uncertain and cannot
be predicted, and which may have a material adverse impact on
Bausch Health, including but not limited to its project development
timelines, and costs (which may increase). Readers are cautioned
not to place undue reliance on any of these forward-looking
statements. These forward-looking statements speak only as of the
date hereof. Bausch Health undertakes no obligation to update any
of these forward-looking statements to reflect events or
circumstances after the date of this news release or to reflect
actual outcomes, unless required by law.
*Versus leading silicone hydrogel daily disposables, DAILIES
TOTAL1 and ACUVUE OASYS 1-DAY, based on dollar share of
segment.
INFUSE is a trademark of Bausch & Lomb Incorporated or its
affiliates.
© 2020 Bausch & Lomb Incorporated or its
affiliates.
INF.0166.USA.20
- National Institutes of Health.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2628947/
- American Optometric Association.
https://www.aoa.org/patients-and-public/caring-for-your-vision/contact-lenses/facts-and-stats
- Centers for Disease Control and Prevention.
https://www.cdc.gov/contactlenses/fast-facts.html#:~:text=An%20estimated%2045%20million%20people,is%2031%20years%20old%202
Investor
Contact:
|
Media
Contact:
|
Arthur
Shannon
|
Lainie
Keller
|
arthur.shannon@bauschhealth.com
|
lainie.keller@bauschhealth.com
|
(514)
856-3855
|
(908)
927-1198
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bausch--lomb-launches-innovative-bausch--lomb-infuse-silicone-hydrogel-sihy-daily-disposable-contact-lenses-301112825.html
SOURCE Bausch Health Companies Inc.